5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CRF 1 Receptor Signaling via the ERK1/2-MAP and Akt Kinase Cascades: Roles of Src, EGF Receptor, and PI3-Kinase Mechanisms

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the present study, we determined the cellular regulators of ERK1/2 and Akt signaling pathways in response to human CRF 1 receptor (CRF 1R) activation in transfected COS-7 cells. We found that Pertussis Toxin (PTX) treatment or sequestering Gβγ reduced CRF 1R-mediated activation of ERK1/2, suggesting the involvement of a G i-linked cascade. Neither G s/PKA nor G q/PKC were associated with ERK1/2 activation. Besides, CRF induced EGF receptor (EGFR) phosphorylation at Tyr 1068, and selective inhibition of EGFR kinase activity by AG1478 strongly inhibited the CRF 1R-mediated phosphorylation of ERK1/2, indicating the participation of EGFR transactivation. Furthermore, CRF-induced ERK1/2 phosphorylation was not altered by pretreatment with batimastat, GM6001, or an HB-EGF antibody indicating that metalloproteinase processing of HB-EGF ligands is not required for the CRF-mediated EGFR transactivation. We also observed that CRF induced Src and PYK2 phosphorylation in a Gβγ-dependent manner. Additionally, using the specific Src kinase inhibitor PP2 and the dominant-negative-SrcYF-KM, it was revealed that CRF-stimulated ERK1/2 phosphorylation depends on Src activation. PP2 also blocked the effect of CRF on Src and EGFR (Tyr 845) phosphorylation, further demonstrating the centrality of Src. We identified the formation of a protein complex consisting of CRF 1R, Src, and EGFR facilitates EGFR transactivation and CRF 1R-mediated signaling. CRF stimulated Akt phosphorylation, which was dependent on G i/βγ subunits, and Src activation, however, was only slightly dependent on EGFR transactivation. Moreover, PI3K inhibitors were able to inhibit not only the CRF-induced phosphorylation of Akt, as expected, but also ERK1/2 activation by CRF suggesting a PI3K dependency in the CRF 1R ERK signaling. Finally, CRF-stimulated ERK1/2 activation was similar in the wild-type CRF 1R and the phosphorylation-deficient CRF 1R-Δ386 mutant, which has impaired agonist-dependent β-arrestin-2 recruitment; however, this situation may have resulted from the low β-arrestin expression in the COS-7 cells. When β-arrestin-2 was overexpressed in COS-7 cells, CRF-stimulated ERK1/2 phosphorylation was markedly upregulated. These findings indicate that on the base of a constitutive CRF 1R/EGFR interaction, the G i/βγ subunits upstream activation of Src, PYK2, PI3K, and transactivation of the EGFR are required for CRF 1R signaling via the ERK1/2-MAP kinase pathway. In contrast, Akt activation via CRF 1R is mediated by the Src/PI3K pathway with little contribution of EGFR transactivation.

          Related collections

          Most cited references90

          • Record: found
          • Abstract: found
          • Article: not found

          EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF.

          Cross-communication between different signalling systems allows the integration of the great diversity of stimuli that a cell receives under varying physiological situations. The transactivation of epidermal growth factor receptor (EGFR)-dependent signalling pathways upon stimulation of G-protein-coupled receptors (GPCRs), which are critical for the mitogenic activity of ligands such as lysophosphatidic acid, endothelin, thrombin, bombesin and carbachol, provides evidence for such an interconnected communication network. Here we show that EGFR transactivation upon GPCR stimulation involves proHB-EGF and a metalloproteinase activity that is rapidly induced upon GPCR-ligand interaction. We show that inhibition of proHB-EGF processing blocks GPCR-induced EGFR transactivation and downstream signals. The pathophysiological significance of this mechanism is demonstrated by inhibition of constitutive EGFR activity upon treatment of PC3 prostate carcinoma cells with the metalloproteinase inhibitor batimastat. Together, our results establish a new mechanistic concept for cross-communication among different signalling systems.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation.

            The mechanisms by which mitogenic G-protein-coupled receptors activate the MAP kinase signalling pathway are poorly understood. Candidate protein tyrosine kinases that link G-protein-coupled receptors with MAP kinase include Src family kinases, the epidermal growth factor receptor, Lyn and Syk. Here we show that lysophosphatidic acid (LPA) and bradykinin induce tyrosine phosphorylation of Pyk2 and complex formation between Pyk2 and activated Src. Moreover, tyrosine phosphorylation of Pyk2 leads to binding of the SH2 domain of Src to tyrosine 402 of Pyk2 and activation of Src. Transient overexpression of a dominant interfering mutant of Pyk2 or the protein tyrosine kinase Csk reduces LPA- or bradykinin-induced activation of MAP kinase. LPA- or bradykinin-induced MAP kinase activation was also inhibited by overexpression of dominant interfering mutants of Grb2 and Sos. We propose that Pyk2 acts with Src to link Gi- and Gq-coupled receptors with Grb2 and Sos to activate the MAP kinase signalling pathway in PC12 cells.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mitogenic signaling pathways induced by G protein-coupled receptors.

              G protein-coupled receptor (GPCR) agonists, including neurotransmitters, hormones, chemokines, and bioactive lipids, act as potent cellular growth factors and have been implicated in a variety of normal and abnormal processes, including development, inflammation, and malignant transformation. Typically, the binding of an agonistic ligand to its cognate GPCR triggers the activation of multiple signal transduction pathways that act in a synergistic and combinatorial fashion to relay the mitogenic signal to the nucleus and promote cell proliferation. A rapid increase in the activity of phospholipases C, D, and A2 leading to the synthesis of lipid-derived second messengers, Ca2+ fluxes and subsequent activation of protein phosphorylation cascades, including PKC/PKD, Raf/MEK/ERK, and Akt/mTOR/p70S6K is an important early response to mitogenic GPCR agonists. The EGF receptor (EGFR) tyrosine kinase has emerged as a transducer in the signaling by GPCRs, a process termed transactivation. GPCR signal transduction also induces striking morphological changes and rapid tyrosine phosphorylation of multiple cellular proteins, including the non-receptor tyrosine kinases Src, focal adhesion kinase (FAK), and the adaptor proteins CAS and paxillin. The pathways stimulated by GPCRs are extensively interconnected by synergistic and antagonistic crosstalks that play a critical role in signal transmission, integration, and dissemination. The purpose of this article is to review recent advances in defining the pathways that play a role in transducing mitogenic responses induced by GPCR agonists. 2007 Wiley-Liss, Inc.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrinol.
                Frontiers in Endocrinology
                Frontiers Media S.A.
                1664-2392
                12 December 2019
                2019
                : 10
                : 869
                Affiliations
                [1] 1Laboratory of Signal Transduction, Department of Biochemistry, Center for Research and Advanced Studies of the National Polytechnic Institute, CINVESTAV-IPN , Mexico City, Mexico
                [2] 2Novaliq GmbH , Heidelberg, Germany
                [3] 3Section on Hormonal Regulation, Program on Developmental Endocrinology and Genetics, National Institute of Child Health and Human Development , Bethesda, MD, United States
                [4] 4Center of Excellence for Stress and Mental Health, VA Healthcare System , San Diego, CA, United States
                [5] 5Department of Psychiatry, University of California, San Diego , San Diego, CA, United States
                Author notes

                Edited by: László Hunyady, Semmelweis University, Hungary

                Reviewed by: Mohammed Akli Ayoub, United Arab Emirates University, United Arab Emirates; Craig Alexander McArdle, University of Bristol, United Kingdom

                *Correspondence: J. Alberto Olivares-Reyes jolivare@ 123456cinvestav.mx

                This article was submitted to Cellular Endocrinology, a section of the journal Frontiers in Endocrinology

                †These authors have contributed equally to this work

                Article
                10.3389/fendo.2019.00869
                6921279
                31920979
                f0133bac-0bac-4fd2-a180-e4bffca3df23
                Copyright © 2019 Parra-Mercado, Fuentes-Gonzalez, Hernandez-Aranda, Diaz-Coranguez, Dautzenberg, Catt, Hauger and Olivares-Reyes.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 19 April 2019
                : 27 November 2019
                Page count
                Figures: 14, Tables: 0, Equations: 0, References: 97, Pages: 22, Words: 12643
                Funding
                Funded by: Consejo Nacional de Ciencia y Tecnología 10.13039/501100003141
                Categories
                Endocrinology
                Original Research

                Endocrinology & Diabetes
                corticotropin-releasing factor,crf1 receptor,egf receptor transactivation,erk1/2,src,pi3k/akt

                Comments

                Comment on this article